Brief: Abivax Reports Positive Interim Efficacy And Safety Analysis Of Obefazimod

Abivax SA

03/10/2024 07:39

Oct 3 (Reuters) - Abivax SA  ABVX.PA :
    * REPORTS POSITIVE INTERIM EFFICACY AND SAFETY ANALYSIS OF
OBEFAZIMOD 
    * EFFICACY AND SAFETY DEMONSTRATED OUT TO SIX YEARS
    * SAFETY PROFILE CONSISTENT WITH PREVIOUS STUDIES AND NO NEW
SAFETY SIGNALS DETECTED
    * HIGH PATIENT RETENTION RATES WITH 12% DISCONTINUATION IN
FIRST
YEAR AND 5% DISCONTINUATION IN SECOND YEAR OF TREATMENT
    * OBEFAZIMOD IS ABIVAX'S LEAD INVESTIGATIONAL DRUG CANDIDATE

Source text for Workspace:  urn:newsml:reuters.com:*:nEQ4X5ydWa
Further company coverage:  ABVX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))